标题
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure
作者
关键词
-
出版物
CIRCULATION
Volume 142, Issue 12, Pages 1205-1218
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2020-09-22
DOI
10.1161/circulationaha.120.045888
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
- (2020) Eileen O’Meara et al. CANADIAN JOURNAL OF CARDIOLOGY
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
- (2020) Abhinav Sharma et al. CIRCULATION
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2020 EXECUTIVE SUMMARY
- (2020) Alan J. Garber et al. Endocrine Practice
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Standards of medical care for type 2 diabetes in China‐0027
- (2019) Weiping Jia et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. CIRCULATION
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
- (2019) Maurice B. Bizino et al. Cardiovascular Diabetology
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial
- (2019) Marat Fudim et al. CIRCULATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
- (2019) Ali Aminian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619
- (2019) SHANNON M. DUNLAY et al. JOURNAL OF CARDIAC FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017
- (2019) Andrew Sumarsono et al. JAMA Internal Medicine
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction
- (2018) Goh Eun Chung et al. ATHEROSCLEROSIS
- 2018 Clinical Practice Guidelines Committees
- (2018) Canadian Journal of Diabetes
- Leptin-Aldosterone-Neprilysin Axis
- (2018) Milton Packer CIRCULATION
- Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure
- (2018) Abhinav Sharma et al. Circulation-Heart Failure
- The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest
- (2018) Sebastian Wiberg et al. CRITICAL CARE MEDICINE
- Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
- (2018) Sarita Bajaj International Journal of Diabetes in Developing Countries
- NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL
- (2018) Mansoor Husain et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
- (2018) Chengshi Wang et al. PLoS One
- GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
- (2018) T. Dung Nguyen et al. Journal of Cardiovascular Translational Research
- Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis
- (2018) Karn Wijarnpreecha et al. DIGESTIVE AND LIVER DISEASE
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Effects of intentional weight loss in patients with obesity and heart failure: a systematic review
- (2018) K. McDowell et al. Obesity Reviews
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
- (2018) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Spencer L James et al. LANCET
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis
- (2018) Tannous K. Fakhry et al. Surgery for Obesity and Related Diseases
- Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
- (2018) Jordan Rowlands et al. Frontiers in Endocrinology
- Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney
- (2017) Dilip K. Deb et al. FASEB JOURNAL
- HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin
- (2017) Ulrika Ljung Faxén et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide causes large and rapid epicardial fat reduction
- (2017) Gianluca Iacobellis et al. Obesity
- Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction
- (2017) Sanjiv J. Shah Journal of Cardiovascular Translational Research
- Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
- (2017) Inka Miñambres et al. Diabetology & Metabolic Syndrome
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
- (2017) Michelle Orme et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs
- (2016) Adam D. DeVore et al. AMERICAN JOURNAL OF CARDIOLOGY
- Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β-oxidation in cardiomyocytes via activation of the cardiac renin–angiotensin system and induction of miR-208a
- (2016) Marcel Blumensatt et al. BASIC RESEARCH IN CARDIOLOGY
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
- (2016) Mark M. Smits et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry
- (2016) Giovanni Targher et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction
- (2016) Dalane W. Kitzman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
- (2016) Isabelle Johansson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity
- (2016) R. Burcelin et al. Obesity Reviews
- The effects of bariatric surgeries on nonalcoholic fatty liver disease
- (2016) Tamadar Aldoheyan et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial
- (2015) Alvaro Alonso et al. AMERICAN HEART JOURNAL
- Concomitant Diabetes Mellitus and Heart Failure
- (2015) Alessandra Dei Cas et al. CURRENT PROBLEMS IN CARDIOLOGY
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials
- (2015) Patrick Rossignol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Successful Weight Reduction Improves Left Ventricular Diastolic Function and Physical Performance in Severe Obesity
- (2015) Sabine Fenk et al. International Heart Journal
- Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease
- (2015) Salvatore Petta et al. JOURNAL OF HEPATOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
- (2015) Jacob A Udell et al. Lancet Diabetes & Endocrinology
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
- (2015) Alessandra Dei Cas et al. JACC-Heart Failure
- Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes
- (2015) Alessandro Mantovani et al. PLoS One
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Direct cardiovascular effects of glucagon like peptide-1
- (2013) Asfandyar Sheikh Diabetology & Metabolic Syndrome
- Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis
- (2013) A. Cignarelli et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Meta-Analysis of the Relation of Echocardiographic Epicardial Adipose Tissue Thickness and the Metabolic Syndrome
- (2012) Sante D. Pierdomenico et al. AMERICAN JOURNAL OF CARDIOLOGY
- High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
- (2012) L. J. M. Boonman-de Winter et al. DIABETOLOGIA
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
- (2012) Stuart J. Pocock et al. EUROPEAN HEART JOURNAL
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now